Staff Writer
The Post-Venture Capital Index slipped over the month to 1028.62 at end of March, but stands more than 143 points above year-ago mark
Jeremy Liew of Lightspeed Venture Partners, Margaux Avedisian of BlockStream Ventures, Brian Hirsch of Tribeca Venture Partners, and Barry Silbert of SecondMarket discuss the promise of digital currency and the challenges ahead.
Colin Ambrose of UJA-Federation of New York, Anne Dinneen of The James Irvine Foundation and Tom Lenehan of Rockefeller University talk about what’s compelling in alternative investments for endowments and foundations.
U.S.-style VC ecosystem develops in several cities in Europe
With the IPO window nudging open, despite recent setbacks in the broader public markets worldwide, venture-backed companies that in the past might have opted for a trade sale to larger pharmaceutical companies are considering a share listing
Managing Director Maurice Gordon will take over for Turner, who departs effective May 30.
Details on the 18 VC-backed companies that went public on U.S. exchanges in March: 2U, A10 Networks, Achaogen, Aerohive Networks, Akebia Therapeutics, Amber Road, Applied Genetic Technologies, Aquinox Pharmaceuticals, Borderfree, Castlight Health, Coupons.com, Everyday Health, King Digital Entertainment, Mediwound, Paylocity, Q2 Holdings, Recro Pharma and Versartis.
Augment Investments, B.C. Advantage Fund, Baker Brothers, Johnson & Johnson, Pfizer and Ventures West Capital collectively own 6,606,261 shares worth about $73 million at the IPO price.
Alta Partners, Intersouth Partners, InterWest Partners, Medimmune, Osage Partners and Sr One collectively hold 9,123,707 shares worth about $109 million at the IPO price.
Cross Atlantic Capital, Goldman, Sachs, NJTC Investment Fund, Orix Venture Finance and Updata Partners collectively own 12.4 million shares worth $161 million at the IPO price.